MCID: BRS049
MIFTS: 44

Breast Carcinoma in Situ malady

Genetic diseases, Cancer diseases, Rare diseases, Reproductive diseases categories

Aliases & Classifications for Breast Carcinoma in Situ

About this section

Aliases & Descriptions for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 8
Non-Infiltrating Carcinoma of Breast 8
 
Carcinoma in Situ of Breast 8
Stage 0 Breast Carcinoma 61


Classifications:



External Ids:

Disease Ontology8 DOID:8791
ICD9CM27 233.0
NCIt39 C3641
ICD1025 D05

Summaries for Breast Carcinoma in Situ

About this section
MalaCards based summary: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast cancer and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is VEGFC (vascular endothelial growth factor C), and among its related pathways are Fanconi anemia pathway and Homologous Recombination Repair. The compounds topotecan and crcs have been mentioned in the context of this disorder. Affiliated tissues include breast and testes, and related mouse phenotypes are no phenotypic analysis and limbs/digits/tail.

Related Diseases for Breast Carcinoma in Situ

About this section

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Breast Benign Neoplasm
breast carcinoma in situ Familial Breast Cancer
Chek2-Related Susceptibility to Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Hereditary Breast Cancer

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 84)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer31.0BRCA2, BRCA1
2ductal carcinoma in situ29.9TP53, BRCA2, BRCA1, ERBB2, CDH1
3hereditary breast ovarian cancer10.5BRCA2
4chordoma10.4KRT19
5lobular neoplasia10.4
6nodular goiter10.3VEGFC, KRT19
7thyroid carcinoma, follicular10.3KRT19, VEGFC
8thyroid carcinoma, papillary10.3VEGFC, MET
9poland syndrome10.2
10brca1 and brca2 hereditary breast and ovarian cancer10.2BRCA2, BRCA1
11cystadenoma10.2BRCA1, VEGFC
12fallopian tube cancer10.2BRCA2, BRCA1
13peritoneal carcinoma10.2BRCA2, BRCA1
14bilateral breast cancer10.2BRCA2, BRCA1
15lynch syndrome10.2BRCA1, BRCA2
16tongue cancer10.2CDH1, VEGFC
17female breast carcinoma10.2
18breast apocrine carcinoma in situ10.2
19comedo carcinoma10.2
20hypoxia10.2
21dysgerminoma10.2BRCA2, BRCA1
22microinvasive gastric cancer10.2VEGFC, CDH1
23uveal melanoma10.2VEGFC, MET
24cowden disease10.2BRCA2, BRCA1
25gynecomastia10.2BRCA1, BRCA2
26laryngeal carcinoma10.2TP53, VEGFC
27bloom syndrome10.2BRCA1, BRCA2
28tongue squamous cell carcinoma10.2CDH1, KRT19
29neuroendocrine tumor10.1CDH1, KRT19
30nasopharynx carcinoma10.1TP53, CDH1
31aplastic anemia10.1BRCA1, BRCA2
32biliary tract neoplasm10.1MET, ERBB2
33lung benign neoplasm10.1KRT19, MET, TP53
34renal clear cell carcinoma10.1MET, CDH1
35breast fibroadenoma10.1VEGFC, ERBB2
36cervical cancer, somatic10.1VEGFC, TP53, KRT19
37sarcoma, synovial10.1CDH1, KRT19, MET
38follicular adenoma10.1MET, KRT19, CDH1
39mesothelioma, somatic10.0CDH1, MET
40fanconi anemia, complementation group a10.0BRCA1, BRCA2
41malignant mixed mullerian tumor10.0TP53, ERBB2
42esophageal cancer10.0VEGFC, TP53
43li-fraumeni syndrome10.0BRCA1, BRCA2, TP53
44bladder transitional cell carcinoma10.0CDH1, TP53, VEGFC
45xeroderma pigmentosum, variant type10.0BRCA1, TP53
46mesothelioma10.0KRT19, MET
47ataxia-telangiectasia10.0BRCA1, BRCA2, TP53
48thyroid cancer, anaplastic10.0TP53, MET, CDH1
49nasopharyngeal carcinoma10.0VEGFC, TP53, CDH1
50renal cell carcinoma10.0TP53, MET, CDH1

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Symptoms for Breast Carcinoma in Situ

About this section

Drugs & Therapeutics for Breast Carcinoma in Situ

About this section

Drug clinical trials:

Search ClinicalTrials for Breast Carcinoma in Situ

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

About this section

Anatomical Context for Breast Carcinoma in Situ

About this section

MalaCards organs/tissues related to Breast Carcinoma in Situ:

31
Breast, Testes

Animal Models for Breast Carcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

35 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.4MET, CDH1, KRT19, TP53
2MP:00053718.4ERBB2, MET, BRCA1, BRCA2, TP53
3MP:00053888.3ERBB2, MET, BRCA1, TP53
4MP:00053868.2ERBB2, MET, BRCA2, BRCA1, TP53
5MP:00053908.1TP53, KRT19, BRCA2, BRCA1, ERBB2
6MP:00036317.7BRCA2, BRCA1, MET, ERBB2, KRT19, TP53
7MP:00053817.5BRCA1, CDH1, KRT19, ERBB2, MET, TP53
8MP:00053807.5BRCA2, TP53, BRCA1, ERBB2, KRT19, CDH1
9MP:00028737.5CDH1, KRT19, ERBB2, MET, BRCA1, BRCA2
10MP:00053857.5CDH1, ERBB2, TP53, KRT19, VEGFC, MET
11MP:00053787.3CDH1, MET, KRT19, ERBB2, BRCA2, TP53
12MP:00053877.3BRCA2, TP53, SDC1, VEGFC, MET, BRCA1
13MP:00107717.0BRCA1, ERBB2, CDH1, BRCA2, TP53, SDC1
14MP:00053897.0CDH1, BRCA2, TP53, SDC1, BRCA1, ERBB2
15MP:00053766.8MET, CDH1, BRCA2, ERBB2, SDC1, BRCA1
16MP:00020066.7ERBB2, CDH1, KRT19, MET, BRCA1, SDC1
17MP:00053796.7CDH1, KRT19, BRCA2, SDC1, TP53, BRCA1
18MP:00053846.7MET, CDH1, ERBB2, KRT19, SDC1, TP53
19MP:00107686.4TP53, MET, CDH1, KRT19, ERBB2, BRCA1

Publications for Breast Carcinoma in Situ

About this section

Articles related to Breast Carcinoma in Situ:

(show all 40)
idTitleAuthorsYear
1
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. (22595929)
2012
2
Differences in breast carcinoma in situ between menopausal and premenopausal women. (21617240)
2011
3
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. (21149333)
2010
4
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. (20565829)
2010
5
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? (19896281)
2010
6
Prevalence of breast carcinoma in situ in the United States. (19706857)
2009
7
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. (18665169)
2008
8
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). (18317962)
2008
9
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. (17244359)
2007
10
Cigarette smoking and risk of breast carcinoma in situ. (17700252)
2007
11
Oral contraceptive use and risk of breast carcinoma in situ. (18006914)
2007
12
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. (17063272)
2007
13
Quality of life for women diagnosed with breast carcinoma in situ. (17050872)
2006
14
Molecular classification of breast carcinoma in situ. (17375183)
2006
15
Oral contraceptive use and risk of breast carcinoma in situ (United States). (17006721)
2006
16
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. (15540225)
2005
17
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. (15841074)
2005
18
Impact of reproductive factors and lactation on breast carcinoma in situ risk. (15054874)
2004
19
Proliferative lesions of the breast: carcinoma in situ. (15022899)
2003
20
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. (14659121)
2003
21
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. (12611452)
2003
22
Oral contraceptives and the risk of ductal breast carcinoma in situ. (14572155)
2003
23
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. (12670886)
2003
24
Lifetime recreational exercise activity and risk of breast carcinoma in situ. (14601085)
2003
25
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. (12118344)
2002
26
Breast carcinoma in situ: risk factors and screening patterns. (11734598)
2001
27
p53 mutations and expression in breast carcinoma in situ. (10623666)
2000
28
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. (9622698)
1998
29
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. (9071907)
1997
30
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. (8692711)
1996
31
Biological heterogeneity of breast carcinoma in situ. (8651598)
1996
32
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. (7654052)
1995
33
Breast carcinoma in situ. (20169700)
1992
34
Breast carcinoma-in-situ: an emerging problem in Singapore. (1329232)
1992
35
Receptors for estrogen and progesterone in breast carcinoma in situ. (1295456)
1992
36
Ten-year follow-up of breast carcinoma in situ in Connecticut. (1365682)
1992
37
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. (1677296)
1991
38
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. (1657650)
1991
39
Breast carcinoma in situ. (2535929)
1989
40
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. (2990246)
1985

Variations for Breast Carcinoma in Situ

About this section

Expression for genes affiliated with Breast Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

About this section

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50)    (show all 54)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.7BRCA1, BRCA2
2
Show member pathways
9.7BRCA2, BRCA1
39.7CDH1, MET
49.7CDH1, MET
59.7CDH1, MET
69.4BRCA1, TP53
79.4BRCA1, TP53
89.4BRCA1, TP53
99.4BRCA1, TP53
109.4TP53, BRCA1
119.4TP53, BRCA1
12
Show member pathways
ATM Signaling Pathway36
9.4TP53, BRCA1
139.4TP53, CDH1
14
Show member pathways
9.4VEGFC, MET, CDH1
159.3KRT19, TP53
169.3MET, SDC1
179.3ERBB2, VEGFC, MET
189.2SDC1, CDH1
19
Show member pathways
9.2CDH1, ERBB2, MET
209.2MET, CDH1, ERBB2
219.2CDH1, ERBB2, MET
22
Show member pathways
9.1TP53, BRCA2, BRCA1
239.1TP53, BRCA2, BRCA1
24
Show member pathways
9.1BRCA2, BRCA1, TP53
25
Show member pathways
9.1BRCA2, BRCA1, TP53
26
Show member pathways
9.1TP53, CDH1, MET
27
Show member pathways
9.0TP53, MET, ERBB2
289.0TP53, MET, ERBB2
29
Show member pathways
9.0ERBB2, TP53, BRCA2
30
Show member pathways
Signal transduction PTEN pathway59
8.9ERBB2, CDH1, TP53
318.9CDH1, ERBB2, TP53
32
Show member pathways
8.8ERBB2, MET, VEGFC, CDH1
33
Show member pathways
8.8VEGFC, MET, ERBB2, CDH1
348.8MET, BRCA1, TP53, VEGFC
35
Show member pathways
8.7MET, TP53, VEGFC, ERBB2
36
Show member pathways
8.7MET, ERBB2, VEGFC, TP53
37
Show member pathways
8.7VEGFC, TP53, MET, ERBB2
388.6BRCA2, CDH1, TP53, BRCA1
398.6BRCA1, TP53, MET, ERBB2
40
Show member pathways
Wnt Signaling Pathway NetPath36
8.6SDC1, TP53, CDH1
418.5BRCA1, BRCA2, TP53, ERBB2
42
Show member pathways
Integrin-mediated cell adhesion36
Focal Adhesion36
8.5VEGFC, SDC1, MET, ERBB2
438.2TP53, SDC1, ERBB2, MET
44
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
8.2ERBB2, SDC1, TP53, MET
45
Show member pathways
7.9ERBB2, VEGFC, TP53, BRCA2, MET, BRCA1
467.8VEGFC, TP53, BRCA2, MET, CDH1, ERBB2
47
Show member pathways
7.8CDH1, ERBB2, MET, BRCA1, TP53, VEGFC
48
Show member pathways
7.8VEGFC, TP53, BRCA1, MET, CDH1, ERBB2
49
Show member pathways
Signaling Pathways in Glioblastoma36
7.7TP53, ERBB2, MET, BRCA1, CDH1, BRCA2

Compounds for genes affiliated with Breast Carcinoma in Situ

About this section

Compounds related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50)    (show all 108)
idCompoundScoreTop Affiliating Genes
1topotecan44 1111.4BRCA1
2crcs449.4MET, TP53, CDH1
3o6-methylguanine449.4BRCA2, TP53, CDH1
4methylmethanesulfonate449.4BRCA2, TP53, BRCA1
55-methylcytosine44 2410.3CDH1, BRCA1, TP53
64-hydroxytamoxifen449.3BRCA1, ERBB2, BRCA2
7leptomycin b44 6010.2CDH1, BRCA1, TP53
8gefitinib44 50 1111.2CDH1, ERBB2, MET
9suberoylanilide hydroxamic acid449.1ERBB2, CDH1, TP53
10oxaliplatin44 50 1111.1TP53, BRCA1, ERBB2
11p003449.1CDH1, BRCA2, KRT19, BRCA1
12folate449.1ERBB2, CDH1, BRCA2, BRCA1
13agar449.1BRCA1, CDH1, ERBB2, MET
14methotrexate50 44 1111.0BRCA2, ERBB2, BRCA1, CDH1
15indole-3-carbinol449.0CDH1, BRCA1, BRCA2, TP53
16bortezomib44 50 1111.0TP53, ERBB2, BRCA1
17phosphotyrosine449.0BRCA1, CDH1, ERBB2, MET
18geldanamycin44 50 60 1111.9MET, TP53, CDH1, ERBB2
19resveratrol44 60 24 1111.9BRCA1, BRCA2, ERBB2, TP53
20irinotecan44 50 1110.9CDH1, TP53, ERBB2
21matrigel448.9CDH1, VEGFC, BRCA2, KRT19, MET
22thymidylate448.8TP53, BRCA1, CDH1, ERBB2
235fluorouracil448.8CDH1, ERBB2, TP53, BRCA1
24heparin44 28 24 1111.8VEGFC, CDH1, ERBB2, BRCA1, MET
25bleomycin44 119.8TP53, BRCA1, BRCA2
26estradiol44 24 1110.7BRCA2, KRT19, VEGFC, BRCA1
27genistein44 28 60 1 24 1113.7BRCA2, CDH1, BRCA1, ERBB2, MET
28oligonucleotide448.7BRCA1, TP53, BRCA2, MET, VEGFC
29proline448.6CDH1, BRCA1, TP53, BRCA2, MET
30ly294002448.6VEGFC, TP53, ERBB2, MET, CDH1
31steroid448.6KRT19, ERBB2, BRCA2, BRCA1, MET
32docetaxel44 50 60 1111.5CDH1, BRCA1, ERBB2, TP53, BRCA2
33doxorubicin44 50 1110.5TP53, MET, CDH1, ERBB2, BRCA1
34etoposide44 50 60 1111.5ERBB2, TP53, CDH1, BRCA1, BRCA2
35tamoxifen44 50 28 1111.5BRCA1, CDH1, BRCA2, TP53, ERBB2
36phosphatidylinositol448.5VEGFC, BRCA2, BRCA1, MET, ERBB2, CDH1
37thymidine44 249.3KRT19, MET, BRCA1, TP53, VEGFC, BRCA2
38p002448.3BRCA2, BRCA1, MET, CDH1, KRT19, ERBB2
39cycloheximide448.1BRCA1, TP53, BRCA2, MET, ERBB2, KRT19
40tyrosine448.0CDH1, VEGFC, BRCA1, MET, KRT19, ERBB2
41paclitaxel44 50 1110.0TP53, BRCA1, ERBB2, CDH1, KRT19, BRCA2
42testosterone44 60 24 1111.0BRCA1, VEGFC, MET, ERBB2, KRT19, CDH1
43retinoic acid44 248.9BRCA2, CDH1, KRT19, MET, BRCA1, TP53
44serine447.8TP53, MET, CDH1, ERBB2, KRT19, BRCA1
45vegf447.7TP53, VEGFC, KRT19, BRCA1, MET, ERBB2
46adriamycin447.7CDH1, KRT19, ERBB2, MET, BRCA1, BRCA2
47cisplatin44 50 60 1110.7ERBB2, MET, BRCA2, TP53, CDH1, KRT19
48paraffin447.4ERBB2, KRT19, MET, BRCA1, CDH1, BRCA2
49progesterone44 28 60 24 1111.4TP53, VEGFC, MET, ERBB2, CDH1, KRT19
50estrogen447.3VEGFC, CDH1, BRCA2, BRCA1, MET, ERBB2

GO Terms for genes affiliated with Breast Carcinoma in Situ

About this section

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1focal adhesionGO:00059258.5SDC1, BRCA1, CDH1
2protein complexGO:00432348.1BRCA1, BRCA2, TP53, SDC1
3cytoplasmGO:00057377.3CDH1, ERBB2, BRCA1, BRCA2, TP53, SDC1

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:00716819.9CDH1, BRCA1
2response to X-rayGO:00101659.7BRCA2, TP53
3positive regulation of cell cycle arrestGO:00711589.7BRCA1, TP53
4cell agingGO:00075699.7TP53, BRCA2
5response to gamma radiationGO:00103329.6BRCA2, TP53
6intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:00427719.6BRCA2, TP53
7response to estrogenGO:00436279.5BRCA1, KRT19
8positive regulation of epithelial cell proliferationGO:00506799.5ERBB2, VEGFC
9double-strand break repair via homologous recombinationGO:00007249.4BRCA1, BRCA2
10DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.4BRCA1, BRCA2, TP53
11double-strand break repairGO:00063029.3TP53, BRCA2, BRCA1
12wound healingGO:00420609.1ERBB2, SDC1
13cell proliferationGO:00082839.1ERBB2, MET, TP53
14positive regulation of transcription, DNA-templatedGO:00458938.9TP53, BRCA2, BRCA1, CDH1

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protease bindingGO:00020209.5BRCA2, TP53
2glycoprotein bindingGO:00019488.9CDH1, SDC1
3protein phosphatase bindingGO:00199038.5CDH1, ERBB2, MET, TP53
4protein bindingGO:00055156.0VEGFC, SDC1, TP53, BRCA2, BRCA1, MET

Sources for Breast Carcinoma in Situ

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet